• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Paradigm shift of biological therapy for patients with inflammatory bowel disease after revision of the law on intractable and rare diseases in Japan

Research Project

Project/Area Number 19K19367
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 58010:Medical management and medical sociology-related
Research InstitutionNiigata University (2021-2022)
St. Luke's International University (2019-2020)

Principal Investigator

Saito Shota  新潟大学, 医歯学総合研究科, 客員研究員 (60739465)

Project Period (FY) 2019-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords炎症性腸疾患 / レセプトデータベース / 生物学的製剤 / リアルワールドデータ / 難病法 / データベース解析 / クローン病 / 潰瘍性大腸炎 / QOL / Webアンケート / 難病医療費助成制度 / 生物学的製剤治療 / 医療経済 / 医療政策 / 費用対効果
Outline of Research at the Start

大規模レセプトデータベースを活用した時系列的なビッグデータ解析から難病法改正が及ぼした炎症性腸疾患治療法選択の変化と医療費構造を解明する。

Outline of Final Research Achievements

We clarified that the change of treatment change for patients with inflammatory bowel disease using a claim database after the revision of the law on intractable and rare diseases in Japan. There was no statistically difference in patient age or diagnosis year between 2015 and 2017. However, there were statistically significants between male and female, and diagnosis year after 2018. The results of our study indicated that the rate of biological therapies have been increasing after revision of the law on intractable and rare diseases in Japan.

Academic Significance and Societal Importance of the Research Achievements

炎症性腸疾患治療では積極的な生物学製剤治療によって病勢進行前に症状を抑え込む治療が主流になりつつあるが、難病法の改正が生物学的製剤治療の導入に与えた影響は未解明である。本研究では難病法の改正は患者の治療選択において改悪にはなっていないことが考えられた。また、この10年で生物学的製剤治療はより積極的に行われているようになったことが明らかになった。生物学的製剤治療によって長期の寛解維持が可能となり、その恩恵は大きい。一方で、その医療経済への影響は大きく、本研究成果はバイオシミラーへの置き換えを推進する根拠となり得る。

Report

(5 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (2 results)

All 2021 2020

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results)

  • [Journal Article] Psychological impact of the state of emergency over COVID-19 for non-permanent workers: a Nationwide follow-up study in Japan2021

    • Author(s)
      Saito Shota、Tran Huyen Thi Thanh、Qi Ruan、Suzuki Kenji、Takiguchi Toru、Ishigami Kazuo、Noto Shinichi、Ohde Sachiko、Takahashi Osamu
    • Journal Title

      BMC Public Health

      Volume: 21 Issue: 1 Pages: 334-334

    • DOI

      10.1186/s12889-021-10401-y

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Quality of Life and Eligibility for Specific Financial Assistance for Medical Expenses: A Cross-Sectional Web-Based Survey among Patients with Inflammatory Bowel Disease in Japan2020

    • Author(s)
      Thi Thanh Tran Huyen、Saito Shota、Noto Shinichi、Suzuki Kenji
    • Journal Title

      Gastrointestinal Disorders

      Volume: 2 Issue: 2 Pages: 123-133

    • DOI

      10.3390/gidisord2020012

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2019-04-18   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi